Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ardelyx, Inc. (ARDX : NSDQ)
 
 • Company Description   
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

Number of Employees: 489

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.55 Daily Weekly Monthly
20 Day Moving Average: 4,281,055 shares
Shares Outstanding: 245.25 (millions)
Market Capitalization: $1,606.37 (millions)
Beta: 0.61
52 Week High: $8.40
52 Week Low: $3.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.82% -14.08%
12 Week 9.53% 9.40%
Year To Date 12.35% 11.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Fifth Avenue Suite 210
-
Waltham,MA 02451
USA		 ph: 510-745-1700
fax: 510-745-0493		 investor@ardelyx.com http://www.ardelyx.com
 
 • General Corporate Information   
Officers
Michael Raab - President; Chief Executive Officer and Director
David Mott - Chairman of the Board of Directors
Susan Hohenleitner - Chief Financial Officer
Joseph Reilly - Senior Vice President and Chief Accounting Officer
Robert Bazemore - Director

Peer Information
Ardelyx, Inc. (GSAC)
Ardelyx, Inc. (CASIF)
Ardelyx, Inc. (ALCD.)
Ardelyx, Inc. (OMNN)
Ardelyx, Inc. (CGPI.)
Ardelyx, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 039697107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/07/26
Share - Related Items
Shares Outstanding: 245.25
Most Recent Split Date: (:1)
Beta: 0.61
Market Capitalization: $1,606.37 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.01 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/07/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 436.67
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.53
Price/Cash Flow: -
Price / Sales: 3.94
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 7.82%
vs. Previous Quarter: 13.49%
ROE
12/31/25 - -40.63
09/30/25 - -36.91
06/30/25 - -36.57
ROA
12/31/25 - -13.21
09/30/25 - -12.57
06/30/25 - -13.42
Current Ratio
12/31/25 - 4.31
09/30/25 - 4.41
06/30/25 - 4.30
Quick Ratio
12/31/25 - 4.11
09/30/25 - 4.11
06/30/25 - 4.03
Operating Margin
12/31/25 - -15.12
09/30/25 - -14.20
06/30/25 - -14.60
Net Margin
12/31/25 - -15.12
09/30/25 - -14.20
06/30/25 - -14.60
Pre-Tax Margin
12/31/25 - -14.89
09/30/25 - -13.95
06/30/25 - -14.36
Book Value
12/31/25 - 0.69
09/30/25 - 0.63
06/30/25 - 0.58
Inventory Turnover
12/31/25 - 1.78
09/30/25 - 2.03
06/30/25 - 2.99
Debt-to-Equity
12/31/25 - 1.21
09/30/25 - 1.31
06/30/25 - 1.44
Debt-to-Capital
12/31/25 - 54.85
09/30/25 - 56.71
06/30/25 - 59.08
 

Powered by Zacks Investment Research ©